How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comClinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors
Description:
Based on this, the present study designed and constructed a novel multifunctional molecular DOTA-BLP and its radiolabeled derivative ⁶⁸Ga-DOTA-BLP, aiming to achieve dynamic monitoring of PD-L1 using PET imaging.
Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase:
N/A
Contacts:
xiao chen, PH.Dxiaochen229@tmmu.edu.cn
15922970174
Government Study Link:
NCT07459192 - Click here to see study onClinicalTrials.gov
68Ga-DOTA-BLP
Isotope(s):
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- 17β-estradiol
Chelator: DOTA
Share your feedback
Help us improve your experience